| Literature DB >> 35330234 |
Yiwen Xiao1,2, Weizhong Liang2, Zhibin Zhang1, Ya Wang2, Shanshan Zhang2, Jiantao Liu2, Jun Chang2, Changjiu Ji3, Du Zhu1,2.
Abstract
The secondary metabolites of Phaeosphaeria sp. LF5, an endophytic fungus with acetylcholinesterase (AChE) inhibitory activity isolated from Huperzia serrata, were investigated. Their structures and absolute configurations were elucidated by means of extensive spectroscopic data, including one- and two-dimensional nuclear magnetic resonance (NMR), high-resolution electrospray ionization mass spectrometry (HR-ESI-MS) analyses, and calculations of electronic circular dichroism (ECD). A chemical study on the solid-cultured fungus LF5 resulted in 11 polyketide derivatives, which included three previously undescribed derivatives: aspilactonol I (4), 2-(1-hydroxyethyl)-6-methylisonicotinic acid (7), and 6,8-dihydroxy-3-(1'R, 2'R-dihydroxypropyl)-isocoumarin (9), and two new natural-source-derived aspilactonols (G, H) (2, 3). Moreover, the absolute configuration of de-O-methyldiaporthin (11) was identified for the first time. Compounds 4 and 11 exhibited inhibitory activity against AChE with half maximal inhibitory concentration (IC50) values of 6.26 and 21.18 µM, respectively. Aspilactonol I (4) is the first reported furanone AChE inhibitor (AChEI). The results indicated that Phaeosphaeria is a good source of polyketide derivatives. This study identified intriguing lead compounds for further research and development of new AChEIs.Entities:
Keywords: AChE inhibitor; Phaeosphaeria sp.; biosynthetic pathways; polyketide; secondary metabolite
Year: 2022 PMID: 35330234 PMCID: PMC8955197 DOI: 10.3390/jof8030232
Source DB: PubMed Journal: J Fungi (Basel) ISSN: 2309-608X
Figure 1Chemical structure of compounds 1–11.
Figure 2Signal assignments of compound 4 via 13C and 2D NMR.
The 1H, 13C, HMBC, and HSQC NMR data for compound 4 in CD3OD.
| No. | 1H NMR | 13C NMR | HMBC | HSQC |
|---|---|---|---|---|
| 2 | ― | 176.5 (s) | H-4, H-7 | ― |
| 3 | ― | 131.7 (s) | H-4, H-7, H-8 | ― |
| 4 | 7.36 (1H, br s) | 154.2 (d) | H-5, H-6, H-7 | 7.36 |
| 5 | 5.09 (1H, br q, 6.8) | 79.8 (d) | H-4, H-6 | 5.09 |
| 6 | 1.39 (3H, d, 6.8) | 19.1 (q) | H-5 | 1.39 |
| 7 | 2.30 (1H, br dd, 15.2, 9.1); 2.59 (1H, br d, 15.2) | 29.6 (t) | H-8, H-9 | 2.30, 2.59 |
| 8 | 3.60 (1H, m) | 74.8 (d) | H-7, H-9, H-10 | 3.60 |
| 9 | 3.58 (1H, m) | 71.6 (d) | H-8, H-10 | 3.58 |
| 10 | 1.20 (3H, d, 6.1) | 18.9 (q) | H-8, H-9 | 1.20 |
Figure 3Experimental ECD spectra (200–400 nm) of 4 in MeOH and the calculated ECD spectra of the model molecules of 4 at the PBE0/def2-TZVP level.
Figure 4Calculated 13C chemical shifts against the experimental data of 4.
The 1H, 13C, HMBC, and HSQC NMR data for compound 7 in CD3OD.
| No. | 1H NMR | 13C NMR | HMBC | HSQC( |
|---|---|---|---|---|
| 2 | ― | 166.9 (s) | H-3, H-8 | ― |
| 3 | 7.89 (1H, br s) | 117.5 (d) | H-5 | 7.89 |
| 4 | ― | 142.2 (s) | ― | ― |
| 5 | 7.67 (1H, br s) | 122.6 (d) | H-3, H-10 | 7.67 |
| 6 | ― | 159.5 (s) | H-10, H-5 | ― |
| 7 | 4.89 (1H, overlapped) | 71.1 (d) | H-8 | 4.89 |
| 8 | 1.46 (3H, d, 6.6) | 24.4 (q) | H-7 | 1.36 |
| 9 | ― | 168.4 (s) | H-3, H-5 | ― |
| 10 | 2.59 (3H, s) | 23.7 (q) | H-5 | 2.59 |
Figure 5Signal assignment of compound 7 via 13C and 2D NMR.
Figure 6Experimental ECD spectra (200–400 nm) of 7 in methanol and the calculated ECD spectra of the model molecules of 7 at the PBE0/def2-TZVP level.
Figure 7Signal assignment of compound 9 via 13C and HMBC.
The 1H, 13C, HMBC, and HSQC NMR data for compound 9 in DMSO-d6.
| No. | 1HNMR | 13C NMR | HMBC | HSQC |
|---|---|---|---|---|
| 1 | ― | 165.54 | ― | ― |
| 3 | ― | 157.6 | H-4 | ― |
| 4 | 6.61 (1H, s) | 104.4 | ― | 6.61 |
| 4a | ― | 139.2 | ― | ― |
| 5 | 6.43 (1H, s) | 102.9 | H-4, H-7 | 6.43 |
| 6 | 10.88 (OH, s) | 165.3 | H-7 | ― |
| 7 | 6.33 (1H, s) | 101.5 | ― | 6.33 |
| 8 | 11.00 (OH, s) | 162.5 | H-7 | ― |
| 8a | ― | 97.8 | H-4, H-5, H-7 | ― |
| 1′ | 3.97 (1H, dd) | 74.7 | H-4, H-3′ | 3.97 |
| 2′ | 3.80 (1H, dq) | 67.4 | H-1′, H-3′ | 3.80 |
| 3′ | 1.12 (3H, d) | 19.7 | H-1′ | 1.12 |
Figure 8Experimental ECD spectra (200–400 nm) of 9 in methanol and the calculated ECD spectra of the model molecules of 9 at the PBE0/def2-TZVP level.
Figure 9Experimental ECD spectra (200–400 nm) of 11 in methanol and the calculated ECD spectra of the model molecules of 11 at the PBE0/def2-TZVP level.
Scheme 1Proposed biosynthetic pathways for furanone compounds (1–4).
Scheme 2Proposed biosynthetic pathways for isocoumarin compounds (8–11).
Acetylcholinesterase inhibitory activities of the secondary metabolites of Phaeosphaeria sp. LF5, expressed as IC50 values.
| Compound | IC50 (µM) a | Compounds | IC50 (µM) a |
|---|---|---|---|
|
| >100 |
| >100 |
|
| >100 |
| >100 |
|
| >100 |
| >100 |
|
| 6.26 ± 0.15 |
| >100 |
|
| >100 |
| >100 |
| Rivastigmine | 1.82 ± 0.13 |
| 21.18 ± 1.53 |
| Hup-A | 0.045 ± 0.01 |
a Expressed as the mean ± SD of three parallel measurements (p < 0.05).